Read Frequently Asked Questions
Combination Drug/Device Products CGMPs - Final Rule
This training on combination product regulations will evaluate the chief areas of concern or change in the new CGMP requirements for combination products, 21 CFR Part 4, and clarify many of the issues and questions that arise involving combination products.
Why Should You Attend:
There has been much past confusion on the production and handling of drug / device (and/or biologics) combination products. Companies involved in the production of such products have pieced together what they've considered the applicable elements of the pharma and device CGMPs, 21 CFR 210/211 and 820; sometimes with ambiguous advice from the agency, resulting in some disagreements during compliance audits.
Do not let yourself or your company be caught off guard by the new CGMP requirements for combination products. Attend this training to enhance your awareness of these new cGMP requirements and modify internal audits to match this FDA shift. This training will be a step-by-step review of the key elements of the U.S. FDA's new final rule, "Current Good Manufacturing Practice Requirements for Combination Products", 21 CFR Part 4. The presenter will evaluate and clarify many of the pertinent issues and questions that arise involving combination products.
This session will provide valuable assistance to all regulated companies in evaluating their existing or proposed CGMP compliance and internal audit emphasis for the production of combination products, as a sub-contractor or primary manufacturer. Once you have recognized the danger and likely locations of potential problem areas, a company can evaluate / perform a gap analysis, and then put in place the necessary fixes to ensure compliance to the new rule.
Areas Covered in the Webinar:
- The Four Basic Types of Combination Products
- two or more of device, drug, biologic;
- physically combined; or
- packaged together; or
- packaged separately but intended for use only with another, different type of medical product ("cross-labeling").
Who Will Benefit:
This training applies to personnel / companies primarily in the pharmaceutical, medical device, and biologics fields. The employees who will benefit include:
- Senior management
- Regulatory affairs
- Quality assurance
- All personnel involved in a U.S. FDA-regulated environment; especially those involved in CGMP compliance of affected regulated combination medical products
John E. Lincoln is principal of J. E. Lincoln and Associates LLC, a consulting company with over 31 years’ experience in U.S. FDA-regulated industries, and 17 years as a full-time consultant. Mr. Lincoln has worked with companies from start-up to Fortune 100, in the U.S., Mexico, Canada, France, Germany, Sweden, China and Taiwan. He specializes in quality assurance, regulatory affairs, QMS problem remediation and FDA responses, new / changed product 510(k)s, process / product / equipment including QMS and software validations, ISO 14971 product risk management files / reports, design control / design history files, and technical files. He's held positions in manufacturing engineering, QA, QAE, regulatory affairs, to the level of director and VP (R&D). In addition, Mr. Lincoln has prior experience in military, government, electronics, and aerospace. He has published numerous articles in peer reviewed journals, conducted workshops and webinars worldwide on CAPA, 510(k)s, risk analysis / management, FDA / GMP audits, validation, root cause analysis, and others. Mr. Lincoln is a graduate of UCLA.
The U.S. FDA has issued the long-awaited CGMPs for Drug / Device and/ or Biologics Combination Products - 21 CFR Part 4, Final Rule, effective July 22, 2013.
This new final rule, "Current Good Manufacturing Practice Requirements for Combination Products", 21 CFR Part 4, clarifies many of these issues involving combination products including: 1) two or more of device, drug, biologic; 2) physically combined; or 3) packaged together; or 4) packaged separately but intended for use only with another, different type of medical product ("cross-labeling"). While the constituent parts of a combination product retain their regulatory status, there have not been specific regulations clarifying the applicability of the CGMPs to such combinations.
ComplianceOnline would process/provide refund only if the Live Webinar has been cancelled. The attendee could choose between the recorded version of the webinar or refund for any cancelled webinar. Refunds will not be given to participants who do not show up for the webinar. On-Demand Recordings can be requested in exchange. Webinar may be cancelled due to lack of enrolment or unavoidable factors. Registrants will be notified 24hours in advance if a cancellation occurs."
For substitution, please email firstname.lastname@example.org or call +1-650-620-3937.
This training hasn't been reviewed yet.
John E Lincoln
10 Steps to Effective Risk Analysis for US FDA and ISO 14971 Compliance Risk-Based Verification and Validation Planning to Meet US FDA and ISO 13485 Requirements Change Control - Implementation and Management Validation for FDA and ISO 13485 Compliance: Pack of Two Courses